Koyama Motoi, Murata Akihiko, Kimura Yutaka, Sakamoto Yoshiyuki, Morohashi Hajime, Kimura Norihisa, Gasa Fujihiko, Sato Junya, Terui Kazushi, Awatsu Akemi, Hakamada Kenichi
Department of Gastroenterological Surgery, Hirosaki University Graduate School of Medicine.
Gan To Kagaku Ryoho. 2010 Jun;37(6):1069-73.
We retrospectively investigated the safety and efficacy on outpatient chemotherapy including bevacizumab(BV)as secondline therapy for inoperable metastatic colorectal cancer. Analytical subjects were thirty patients treated with chemotherapy including BV as second-line therapy after first disease progression. All patients were treated with BV 5mg/kg. Concurrent therapy was given mFOLFOX6(2 patients)and FOLFIRI(28 patients). The BV treatment frequency and all course treatment frequency including the prior regimens averaged 20 and 37 times, respectively. The overall response rate was 24. 1%(PR, 7 patients; SD, 17 patients; PD, 5 patients), and the median duration of progression-free survival was 8. 0 months. The median duration of survival after addition of BV was 20. 3 months. The adverse events were 84%(>grade 3, 9%), BV-associated adverse events were GI perforation(1 patient), GI hemorrhage(1 patient), grade 3 hypertension(1 patient)and grade 2 epitaxis(2 patient). Although it is necessary to be careful about GI hemorrhage and GI perforation, we could safely continue the treatment with BV on outpatient chemotherapy. We confirmed that the chemotherapy including BV as second-line therapy had high antitumor effect and patient benefit.
我们回顾性研究了贝伐单抗（BV）作为不可切除转移性结直肠癌二线治疗的门诊化疗的安全性和疗效。分析对象为30例在首次疾病进展后接受包括BV在内的化疗作为二线治疗的患者。所有患者均接受5mg/kg的BV治疗。同时给予mFOLFOX6治疗2例患者，FOLFIRI治疗28例患者。BV治疗频率以及包括先前治疗方案在内的整个疗程治疗频率平均分别为20次和37次。总缓解率为24.1%（PR，7例患者；SD，17例患者；PD，5例患者），无进展生存期的中位数为8.0个月。加用BV后的生存期中位数为20.3个月。不良事件发生率为84%（>3级，9%），与BV相关的不良事件为胃肠道穿孔（1例患者）、胃肠道出血（1例患者）、3级高血压（1例患者）和2级鼻出血（2例患者）。尽管有必要注意胃肠道出血和胃肠道穿孔，但我们可以在门诊化疗中安全地继续使用BV进行治疗。我们证实，包括BV作为二线治疗的化疗具有较高的抗肿瘤效果且对患者有益。
